Form D · Biotechnology
Azure Biotech, Inc.
New York, NY · CIK 0001630005
Offering snapshot reported May 6, 2022 · SEC filing
- Reported sold
- $2.69M Offering amount: $2.69M
- Investors reported
- 78 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 27, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 6, 2022 | Initial | $2,691,012 | No comparison | 78 | SEC filing |
| Jan 7, 2015 | Initial | $355,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-444806
Source: Form D, filed May 6, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Valerie Ceva | Director, Executive |
| Steven R. Goldstein | Director |
| Susan Levinson | Director |
| Ralph Makar | Executive |
| David D. Thompson | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
500 East 85th Street 19 D
New York, NY, 10025
New York, NY, 10025